Navigation Links
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Date:11/6/2011

www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

References

  1. ACZ885 G2305 SJIA presentation (both G2305 and G2301) Brunner H, Ruperto N, Horneff G, et al. Efficacy and safety of canakinumab, a fully human anti-interleukin-1beta antibody, in active systemic juvenile idiopathic arthritis: Results from two Phase III studies. Presented on 9 November: The 2011 ACR Annual Scientific Meeting; November 5-9, 2011, Chicago, US. 2011.
  2. Woo P. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol 2006; 2(1):28-34
  3. Bailey KM, McDonagh JE, Prieur AM. Systemic juvenile idiopathic arthritis presenting in a young child with long term disability as an adolescent. Ann Rheum Dis 2004; 63(12):1544-8.
  4. Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 2011; 7(7):416-26.
  5. Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol 2008; 4(1):34-42.
  6. Ramanan AV, Grom AA. Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis? Rheumatology (Oxford) 2005; 44(11):1350-3.
  7. Novartis data on file. Abrams K, Dimitrov-Kuhl M, Doerr T et al.  Clinical Study Protocol (CACZ885G2301): beta-SPECIFIC 2: Study of Pediatric EffiCacy wIth FIrst-line use of Canakinumab [A randomized, double-blind, placebo controlled, withdrawal study of flare prevention of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations].  23 May 2011.

Novartis Media Relations 


'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Ipsen ... IPN; ADR: IPSEY), today announced that ... to as Somatuline®) was approved by the U.S. ... of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients ... or metastatic disease to improve progression-free survival (PFS). ...
(Date:12/17/2014)... 17, 2014 This report is ... Tubing industry. For an overview analysis, the report ... industry chain structure, industry overview, policy analysis, and ... industry has witnessed rapid development with key ... acquisitions. This report mentions quartz tubing upstream raw ...
(Date:12/17/2014)... Menlo Park, CA (PRWEB) December 17, 2014 ... Inc. announces today that it has entered into ... Daniels Midland Company (ADM) to apply DNA2.0’s proprietary ... industrial enzyme engineering process. , “We are extremely ... our ProteinGPS engineering platform. This proprietary bioengineering ...
(Date:12/17/2014)... 16, 2014  Vermillion, Inc. (NASDAQ: VRML ... today announced the next step in its expanded strategy ... provider with the naming of current Chief Operating Officer, ... Officer, while current Chairman of the Board and CEO ... Chairman. These changes are effective January 1, 2015. ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 82020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4
... Herremans Joins SPO Medical to Endorse New... -- NEW YORK, October 5, 2010 ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
... Ore. Nanotechnology is about to emerge in the world ... approaches are needed to understand the implications for public health, ... and prevent possible risks, researchers say in a new report. ... Journal of Occupational and Environmental Health , scientists from Oregon ...
... Reportlinker.com announces that a new market research report ... Global Soft Tissue Allografts Industry ... the worldwide markets for Soft Tissue Allografts in ... Meniscus Allografts, and Tendon Allografts. The report provides ...
Cached Biology Technology:Philadelphia Eagles' Offensive Lineman Todd Herremans Joins SPO Medical to Endorse New SPO Wellness(TM) Product Line 2Philadelphia Eagles' Offensive Lineman Todd Herremans Joins SPO Medical to Endorse New SPO Wellness(TM) Product Line 3Philadelphia Eagles' Offensive Lineman Todd Herremans Joins SPO Medical to Endorse New SPO Wellness(TM) Product Line 4Philadelphia Eagles' Offensive Lineman Todd Herremans Joins SPO Medical to Endorse New SPO Wellness(TM) Product Line 5Philadelphia Eagles' Offensive Lineman Todd Herremans Joins SPO Medical to Endorse New SPO Wellness(TM) Product Line 6Philadelphia Eagles' Offensive Lineman Todd Herremans Joins SPO Medical to Endorse New SPO Wellness(TM) Product Line 7Philadelphia Eagles' Offensive Lineman Todd Herremans Joins SPO Medical to Endorse New SPO Wellness(TM) Product Line 8Philadelphia Eagles' Offensive Lineman Todd Herremans Joins SPO Medical to Endorse New SPO Wellness(TM) Product Line 9Philadelphia Eagles' Offensive Lineman Todd Herremans Joins SPO Medical to Endorse New SPO Wellness(TM) Product Line 10New approaches needed to gauge safety of nanotech-based pesticides 2New approaches needed to gauge safety of nanotech-based pesticides 3Reportlinker Adds Global Soft Tissue Allografts Industry 2Reportlinker Adds Global Soft Tissue Allografts Industry 3Reportlinker Adds Global Soft Tissue Allografts Industry 4Reportlinker Adds Global Soft Tissue Allografts Industry 5Reportlinker Adds Global Soft Tissue Allografts Industry 6Reportlinker Adds Global Soft Tissue Allografts Industry 7Reportlinker Adds Global Soft Tissue Allografts Industry 8Reportlinker Adds Global Soft Tissue Allografts Industry 9Reportlinker Adds Global Soft Tissue Allografts Industry 10Reportlinker Adds Global Soft Tissue Allografts Industry 11
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays ... a while. Hypertension – the medical term for high blood ... early 1800s, and the inflatable cuff that,s used in measuring ... however, mean there,s nothing new about hypertension, its triggers and ... beliefs about the condition and the best ways to treat ...
(Date:12/10/2014)... 2014 CIE San Diego has launched an ... connective tissue that enhances care coordination among social service ... client-level information; earned a second $1 million grant from ... seniors aging in community and; will be recognized as ... th 4-6p. CIE San Diego today ...
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... been shed on proteorhodopsin, the light-sensitive protein found in ... of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) and ... when the ability to respire oxygen is impaired, bacterium ... carry out vital life processes. , ...
... an increased risk of fetal heart problems when mothers ... an abstract presented by Yale School of Medicine researchers ... in San Francisco. , Congenital heart block (CHB) ... heart's electrical signaling from the upper to the lower ...
... system to produce antibodies that act against some essential ... can act against sperm, eggs or reproductive hormones, which ... ova. , Proponents of the technique, which ... as more humane than the conventional methods of controlling ...
Cached Biology News:Shedding new light on proteorhodopsin 2Shedding new light on proteorhodopsin 3Manipulating nature: Scientists query wildlife birth-control method 2
... II identification and library ... module that adds capabilities ... and identification of unknowns ... entries of the same ...
Fingerprinting II cluster analysis is an optional module that adds dendrogram and phylogenetic tree construction, cluster and group significance, and congruence of techniques functions to the Fingerp...
Fingerprinting II Informatix optional matrix types module, is an optional module that adds external similarity and distance matrix functions to the Fingerprinting II Informatix software package....
... ,High Quality, Functionally-Validated, Ion Channel Cell Lines ... having a critical role in nerve and ... function in pain, CNS and the heart. ... investigated in therapeutic areas, such as neuropathic ...
Biology Products: